Literature DB >> 15253941

Will oral antithrombin agents replace warfarin?

P R Sinnaeve, F J Van de Werf.   

Abstract

The new oral direct thrombin inhibitor ximelagatran is at least equivalent to warfarin for stroke prevention in patients with non-valvar atrial fibrillation, and seems to be a promising adjunct to aspirin after acute coronary syndrome

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15253941      PMCID： PMC1768393          DOI： 10.1136/hrt.2003.030379

Source DB:  PubMed          Journal:  Heart        ISSN： 1355-6037            Impact factor:   5.994


  20 in total

1.  In vitro and in vivo evaluation of oral heparin-loaded polymeric nanoparticles in rabbits.

Authors:  Yuyan Jiao; Nathalie Ubrich; Monique Marchand-Arvier; Claude Vigneron; Maurice Hoffman; Thomas Lecompte; Philippe Maincent
Journal:  Circulation       Date:  2002-01-15       Impact factor: 29.690

2.  Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial.

Authors:  Bengt I Eriksson; David Bergqvist; Peter Kälebo; Ola E Dahl; Siv Lindbratt; Anders Bylock; Lars Frison; Ulf G Eriksson; Lennart Welin; David Gustafsson
Journal:  Lancet       Date:  2002-11-09       Impact factor: 79.321

3.  A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study.

Authors:  P K Coussement; J P Bassand; C Convens; M Vrolix; J Boland; G Grollier; R Michels; A Vahanian; M Vanderheyden; H J Rupprecht; F Van de Werf
Journal:  Eur Heart J       Date:  2001-09       Impact factor: 29.983

4.  Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis.

Authors:  E M Antman; M Cohen; D Radley; C McCabe; J Rush; J Premmereur; E Braunwald
Journal:  Circulation       Date:  1999-10-12       Impact factor: 29.690

5.  Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial.

Authors:  Robert F van Es; Jan J C Jonker; Freek W A Verheugt; Jaap W Deckers; Diederick E Grobbee
Journal:  Lancet       Date:  2002-07-13       Impact factor: 79.321

6.  The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study.

Authors:  B I Eriksson; G Agnelli; A T Cohen; O E Dahl; M R Lassen; P Mouret; N Rosencher; P Kälebo; S Panfilov; C Eskilson; M Andersson; A Freij
Journal:  J Thromb Haemost       Date:  2003-12       Impact factor: 5.824

7.  Warfarin, aspirin, or both after myocardial infarction.

Authors:  Mette Hurlen; Michael Abdelnoor; Pål Smith; Jan Erikssen; Harald Arnesen
Journal:  N Engl J Med       Date:  2002-09-26       Impact factor: 91.245

8.  Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial.

Authors:  Lars Wallentin; Robert G Wilcox; W Douglas Weaver; Håkan Emanuelsson; Andrew Goodvin; Per Nyström; Anders Bylock
Journal:  Lancet       Date:  2003-09-06       Impact factor: 79.321

9.  Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement.

Authors:  Charles W Francis; Scott D Berkowitz; Philip C Comp; Jay R Lieberman; Jeffrey S Ginsberg; Guy Paiement; Gary R Peters; Anne W Roth; Jennifer McElhattan; Clifford W Colwell
Journal:  N Engl J Med       Date:  2003-10-30       Impact factor: 91.245

10.  Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial.

Authors:  S Bertil Olsson
Journal:  Lancet       Date:  2003-11-22       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.